%0 Generic
%A Owonikoko, T. K.
%A Kim, H. R.
%A Govindan, R.
%A Ready, N.
%A Reck, M.
%A Peters, S.
%A Dakhil, S. R.
%A Navarro, A.
%A Rodriguez-Cid, J.
%A Schenker, M.
%A Lee, J. S.
%A Gutierrez, V.
%A Percent, I.
%A Morgensztern, D.
%A Fairchild, J.
%A Baudelet, C.
%A Park, K.
%T Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study
%D 2019
%@ 0923-7534
%U https://hdl.handle.net/10668/24385
%~